Comparison of the efficacy of topical N-acetyl-cysteine and a topical steroid-antibiotic combination therapy in the treatment of meibomian gland dysfunction

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 1, 2012, Pages 49-52

  Akyol Salman, Ilknur ^a   Azizi, Sedat ^a   Mumcu, Uǧur Yilmaz ^a   Ateş, Orhan ^a   Baykal, Orhan ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETAMETHASONE; BETAMETHASONE PLUS SULFACETAMIDE SODIUM; BRUMETON; SULFACETAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ARTICLE; BLEPHARITIS; BLURRED VISION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EYE BURNING; EYELID; FEMALE; FLUORESCEIN BREAK UP TIME; HUMAN; INTRAOCULAR PRESSURE; MALE; MEIBOMIAN GLAND DYSFUNCTION; OCULAR PRURITUS; PERSONAL HYGIENE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SCORING SYSTEM; SIDE EFFECT; STEROID THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME; VISUAL DISORDER; VISUAL SYSTEM EXAMINATION;

ACETYLCYSTEINE; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; BETAMETHASONE; DRUG COMBINATIONS; EYELID DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MEIBOMIAN GLANDS; MIDDLE AGED; PROSPECTIVE STUDIES; SULFACETAMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856872172     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2010.0110     Document Type: Article

References (37)

1. Driver, P.J., and Lemp, M.A. Seborrhea and meibomian gland dysfunction. In: Krachmer, J.H., Mannis, M.J., Holland, E.J., eds. Cornea: Fundamentals, Diagnosis and Management. Philadelphia: Elsevier Mosby; 2005; p. 485-491.
2. Jackson, W.B. Blepharitis: current strategies for diagnosis and management. Can. J. Ophthalmol. 43:170-179, 2008. (Pubitemid 351518168)
3. Mathers, W.D. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology 100:347-351, 1993. (Pubitemid 23088533)
4. McCulley, J.P., and Shine, W.E. Changing concepts in the diagnosis and management of blepharitis. Cornea 19:650-658, 2000.
5. Bron, A.J., and Tiffany, J.M. The contribution of meibomian disease to dry eye. Ocul. Surf. 2:149-165, 2004.
6. Romero, J.M., Biser, S.A., Perry, H.D., et al. Conservative treatment of meibomian gland dysfunction. Eye Contact Lens. 30:14-19, 2004. (Pubitemid 43196973)
7. Smith, R.E., and Flowers, Jr., C.W. Chronic blepharitis: a review. CLAO J. 21:200-207, 1995.
8. Driver, P.J., and Lemp, M.A. Meibomian gland dysfunction. Surv. Ophthalmol. 40:343-367, 1996. (Pubitemid 26117272)
9. McCulley, J.P. Blepharoconjunctivitis. Int. Ophthalmol. Clin. 24:65-77, 1984.
10. Dougherty, J.M., McCulley, J.P., Silvany, R.E., and Meyer, D.R. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest. Ophthalmol. Vis. Sci. 32:2970-2975, 1991.
11. Rubin, M., and Rao, S.N. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J. Ocul. Pharmacol. Ther. 22:47-53, 2006. (Pubitemid 43364080)
12. Perry, H.D., Doshi-Carnevale, S., Donnenfeld, E.D., et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 25:171-175, 2006. (Pubitemid 43362715)
13. Goto, E., Shimazaki, J., Monden, Y., et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology 109:2030-2035, 2002. (Pubitemid 35222556)
14. Macsai, M.S. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans. Am. Ophthalmol. Soc. 106:336-356, 2008.
15. Ziment, I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed. Pharmacother. 42:513-519, 1988. (Pubitemid 19027368)
16. Sadowska, A.M., Verbraecken, J., Darquennes, K., and De Backer, W.A. Role of N-acetylcysteine in the management of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 1:425-434, 2006.
17. Pelle, E., Ingrassia, M., Mammone, T., Marenus, K., and Maes, D. Protection against cigarette smoke-induced damage to intact transformed rabbit corneal cells by N-acetyl-L-cysteine. Cell Biol. Toxicol. 14:253-259, 1998. (Pubitemid 28375846)
18. Absolon, M.J., and Brown, C.A. Acetylcysteine in kerato-conjunctivitis sicca. Br. J. Ophthalmol. 52:310-316, 1968.
19. Slansky, H.H., Berman, M.B., Dohlman, C.H., and Rose, J. Cysteine and acetylcysteine in the prevention of corneal ulcerations. Ann. Ophthalmol. 2:488-493, 1970.
20. Haut, J., Labrune, P., and Ullern, M. New trial treatment of dry eye with acetylcysteine ophthalmic solution. Bull. Soc. Ophthalmol. Fr. 77:165-167, 1977.
21. Brown, S.I., and Weller, C.A. Collagenase inhibitors in prevention of ulcers alkali-burned cornea. Arch. Ophthalmol. 83:352-353, 1970.
22. Brown, S.I., Tragakis, M., and Pearce, D. Treatment of the alkali-burned cornea. Am. J. Ophthalmol. 74:316-320, 1972.
23. Williamson, J., Doig, W.M., Forrester, J.V., et al. Management of the dry eye in Sjögren's syndrome. Br. J. Ophthalmol. 58:798-805, 1974.
24. Berman, M.B. Collagenase inhibitors: Rationale for their use in treating corneal ulceration. Int. Ophthalmol. Clin. 15:49-66, 1975.
25. Fraunfelder, F.T., Wright, P., and Tripathi, R.C. Corneal mucus plaques. Am. J. Ophthalmol. 83:191-197, 1977. (Pubitemid 8041924)
26. Marsh, R.J., and Cooper, M. Ophthalmic zoster: Mucous plaque keratitis. Br. J. Ophthalmol. 71:725-728, 1987. (Pubitemid 17148496)
27. Pocupec, R., Petricek, I., Sikic, J., et al. Comparison of local acetylcysteine and artificial tears in the management of dry eye syndrome. Acta Med. Croatica. 59:337-340, 2005. (Pubitemid 47050792)
28. Yalçin, E., Altin, F., Cinhü seyinoglue, F., and Arslan, M.O. N-acetylcysteine in chronic blepharitis. Cornea 21:164-168, 2002. (Pubitemid 34188783)
29. Akyol-Salman, I., Azizi, S., Mumcu, U., and Baykal, O. Efficacy of topical N-Acetylcysteine in the treatment of mei-bomian gland dysfunction. J. Ocul. Pharmacol. Ther. 26:329-333, 2010.
30. Pflugfelder, S.C., Solomon, A., and Stern, M.E. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 19:644-649, 2000.
31. Solomon, A., Dursun, D., Liu, Z., et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest. Oph-thalmol. Vis. Sci. 42: 2283-2292, 2001. (Pubitemid 32848857)
32. Korb, D.R., Scaffidi, R.C., Greiner, J.V., et al. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. Optom. Vis. Sci. 82:594-601, 2005. (Pubitemid 41060347)
33. Pisella, P.J., Brignole, F., Debbasch, C., et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology 107:1841-1849, 2000.
34. Lanza, L., Scudeletti, M., Monaco, E., et al. Possible differences in the mechanism(s) of action of different glucocorti-coid hormone compounds. Ann. N. Y. Acad. Sci. 876:193-197, 1999. (Pubitemid 29352125)
35. Marquart, M., Bhattacharjee, P., Zheng, X., et al. Ocular reactivation phenotype of HSV-1 strain F(MP)E, a corticoste-roid-sensitive strain. Curr. Eye Res. 26:205-209, 2003. (Pubitemid 36829647)
36. Wilhelmus, K.R., Dawson, C.R., Barron, B.A., et al. Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Her-petic Eye Disease Study Group. Br. J. Ophthalmol. 80:969-972, 1996. (Pubitemid 26413698)
37. Carnahan, M.C., and Goldstein, D.A. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr. Opin. Ophthalmol. 11:478-483, 2000.